This document discloses molecules having the following formula (Formula One): ##STR00001##
and processes associated therewith.

This document discloses molecules having the following formula (Formula One): ##STR00001##
and processes associated therewith.

This document discloses molecules having the following formula (Formula One):

##STR00001##

and processes associated therewith.

This document discloses molecules having the following formula (Formula One):

##STR00001##

and processes associated therewith.

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) ##STR00001##
wherein
X, Y, Z, R, R.sub.1, R.sub.2, R.sub.3, R.sub.3 R.sub.4, R.sub.5, R.sub.6, R.sub.7 have the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) ##STR00001##
wherein
X, Y, Z, R, R.sub.1, R.sub.2, R.sub.3, R.sub.3 R.sub.4, R.sub.5, R.sub.6, R.sub.7 have the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) ##STR00001##
wherein
X, Y, Z, R, R.sub.1, R.sub.2, R.sub.3, R.sub.3 R.sub.4, R.sub.5, R.sub.6, R.sub.7 have the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) ##STR00001##
wherein
X, Y, Z, R, R.sub.1, R.sub.2, R.sub.3, R.sub.3 R.sub.4, R.sub.5, R.sub.6, R.sub.7 have the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.

The instant application describes novel compounds that modulate (in particular, inhibit) Sirt2, with structures according to Formulas (1) and (2) provided herein. The invention is also directed to pharmaceutical compositions thereof, methods of treatment (i.e., cancer and neurodegenerative disease) by administration of the modulating compounds, assay methods for finding modulators of Sirt2, and kits for practicing the assay method.

This document discloses molecules having the following formula (Formula One):

##STR00001##

and processes associated therewith.